The Reagan-Udall Foundation for the Food and Drug Administration is a nonprofit organization that was created by Congress to advance the mission of the FDA. The Foundation held a meeting recently entitled “Advancing Treatments for Post-Traumatic Stress Disorder” to discuss efforts to accelerate the development of treatments for PTSD, including psychedelic therapies.

The discussion, hosted by the Reagan-Udall Foundation for the Food and Drug Administration, a nonprofit formed by Congress to support FDA, didn’t focus specifically on psychedelic-assisted therapies, but the topic nevertheless featured prominently—especially during a stakeholder comment session where most spoke in favor of wider access to MDMA and other emerging treatments.

On September 6, the Reagan-Udall Foundation for the Food and Drug Administration, an independent nonprofit created by Congress in 2007 to support the FDA’s mission, hosted a public meeting in Washington, DC, to discuss the latest advancements in post-traumatic stress disorder (PTSD) treatment. Psychedelics were high on the agenda.

Reagan Udall Foundation for the US Food and Drug Administration (FDA), a non-profit organization created by Congress, hosted the hybrid public meeting “Advancing Treatments for Post-Traumatic Stress Disorder” on September 6, 2024.

On Wednesday, the FDA issued a Constituent Update detailing efforts to enhance food traceability. Deputy Commissioner Jim Jones highlighted the FDA’s online resources regarding the Food Traceability Rule, as well as roundtables with the Reagan-Udall Foundation aimed at aiding industry implementation of the Rule. Insights from these discussions will be further explored in an upcoming public meeting on Oct. 7. Stakeholders are encouraged to participate and provide feedback through Oct. 25. For registration details and further information about attending the public meeting please visit the Foundation website.

FMI – The Food Industry Association has expressed its support for the process set forth by the U.S. Food and Drug Administration (FDA) and the nonprofit Reagan-Udall Foundation to solicit feedback from stakeholders about the challenges involved in complying with the FDA’s Food Traceability Rule by Tuesday, Jan. 20, 2026.

Subsequently, the Reagan-Udall Foundation was contracted by the FDA to conduct a series of three invitation-only industry stakeholder meetings focused on FSMA 204 implementation challenges. IFPA attended all of these.

“This is like the weight-loss clinic,” Jenni Wai, Ohio’s chief pharmacist, said of ketamine providers at a June workshop held by the Reagan-Udall Foundation, a congressionally created nonprofit that advises the FDA. “This is like the med spas and the Botox that is popping up everywhere.”

“The Supreme Court’s decision elevates the importance of the Reagan-Udall Foundation’s findings after being convened at the request of the FDA commissioner, which specifically and clearly criticized the FDA’s Center for Tobacco Products for failing to inform companies what must be provided under the regulation to demonstrate APPH [appropriate for the protection of the public health] and, as importantly, for failing to inform the public on how FDA is applying this standard.”

Read more

The meeting, which will be facilitated by the Reagan-Udall Foundation, will provide those in the rare disease community the opportunity to provide input on the priorities of the hub. The FDA plans for the hub to work across rare diseases but especially focus on products intended for smaller populations or for less-understood diseases.